File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Treatment of otitis media by transtympanic delivery of antibiotics

TitleTreatment of otitis media by transtympanic delivery of antibiotics
Authors
Issue Date2016
PublisherAmerican Association for the Advancement of Science. The Journal's web site is located at http://www.sciencemag.org/marketing/stm/
Citation
Science Translational Medicine, 2016, v. 8 n. 356, p. 356ra120 How to Cite?
AbstractOtitis media is the most common reason U.S. children receive antibiotics. The requisite 7- to 10-day course of oral antibiotics can be challenging to deliver in children, entails potential systemic toxicity, and encourages selection of antimicrobial-resistant bacteria. We developed a drug delivery system that, when applied once to the tympanic membrane through the external auditory canal, delivers an entire course of antimicrobial therapy to the middle ear. A pentablock copolymer poloxamer 407–polybutylphosphoester (P407-PBP) was designed to flow easily during application and then to form a mechanically strong hydrogel on the tympanic membrane. U.S. Food and Drug Administration–approved chemical permeation enhancers within the hydrogel assisted flux of the antibiotic ciprofloxacin across the membrane. This drug delivery system completely eradicated otitis media from nontypable Haemophilus influenzae (NTHi) in 10 of 10 chinchillas, whereas only 62.5% of animals receiving 1% ciprofloxacin alone had cleared the infection by day 7. The hydrogel system was biocompatible in the ear, and ciprofloxacin was undetectable systemically (in blood), confirming local drug delivery and activity. This fast-gelling hydrogel could improve compliance, minimize side effects, and prevent systemic distribution of antibiotics in one of the most common pediatric illnesses, possibly minimizing the development of antibiotic resistance.
Persistent Identifierhttp://hdl.handle.net/10722/260279
ISSN
2015 SCImago Journal Rankings: 8.931
PubMed Central ID
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorYang, R-
dc.contributor.authorSabharwal, V-
dc.contributor.authorOkonkwo, OS-
dc.contributor.authorShlykova, N-
dc.contributor.authorTong, R-
dc.contributor.authorLin, LY-
dc.contributor.authorWang, W-
dc.contributor.authorGuo, ST-
dc.contributor.authorRosowski, JJ-
dc.contributor.authorPelton, SI-
dc.contributor.authorKohane, DS-
dc.date.accessioned2018-09-12T07:17:04Z-
dc.date.available2018-09-12T07:17:04Z-
dc.date.issued2016-
dc.identifier.citationScience Translational Medicine, 2016, v. 8 n. 356, p. 356ra120-
dc.identifier.issn1946-6242-
dc.identifier.urihttp://hdl.handle.net/10722/260279-
dc.description.abstractOtitis media is the most common reason U.S. children receive antibiotics. The requisite 7- to 10-day course of oral antibiotics can be challenging to deliver in children, entails potential systemic toxicity, and encourages selection of antimicrobial-resistant bacteria. We developed a drug delivery system that, when applied once to the tympanic membrane through the external auditory canal, delivers an entire course of antimicrobial therapy to the middle ear. A pentablock copolymer poloxamer 407–polybutylphosphoester (P407-PBP) was designed to flow easily during application and then to form a mechanically strong hydrogel on the tympanic membrane. U.S. Food and Drug Administration–approved chemical permeation enhancers within the hydrogel assisted flux of the antibiotic ciprofloxacin across the membrane. This drug delivery system completely eradicated otitis media from nontypable Haemophilus influenzae (NTHi) in 10 of 10 chinchillas, whereas only 62.5% of animals receiving 1% ciprofloxacin alone had cleared the infection by day 7. The hydrogel system was biocompatible in the ear, and ciprofloxacin was undetectable systemically (in blood), confirming local drug delivery and activity. This fast-gelling hydrogel could improve compliance, minimize side effects, and prevent systemic distribution of antibiotics in one of the most common pediatric illnesses, possibly minimizing the development of antibiotic resistance.-
dc.languageeng-
dc.publisherAmerican Association for the Advancement of Science. The Journal's web site is located at http://www.sciencemag.org/marketing/stm/-
dc.relation.ispartofScience Translational Medicine-
dc.rightsScience Translational Medicine. Copyright © American Association for the Advancement of Science.-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.titleTreatment of otitis media by transtympanic delivery of antibiotics-
dc.typeArticle-
dc.identifier.emailWang, W: wangwp@hku.hk-
dc.identifier.authorityWang, W=rp02227-
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.1126/scitranslmed.aaf4363-
dc.identifier.pmid27629487-
dc.identifier.pmcidPMC5615819-
dc.identifier.volume8-
dc.identifier.issue356-
dc.identifier.spage356ra120-
dc.identifier.epage356ra120-
dc.identifier.isiWOS:000384015500002-
dc.publisher.placeUnited States-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats